LLY Analyst Ratings
Eli Lilly and Company (LLY) operates in the Healthcare sector, specifically the Drug Manufacturers - General industry, with a market capitalization near $1.10T, listed on NYSE, employing roughly 50,000 people, carrying a beta of 0.45 to the broader market. Eli Lilly and Company is a prominent global pharmaceutical firm dedicated to the research, development, and commercialization of human medicines across the world. Led by David A. Ricks, public since 1972-06-01.
Analyst Ratings
In the October 2026 monthly count, 30 analysts rated LLY: 6 Strong Buy, 19 Buy, 3 Hold, 1 Sell and 1 Strong Sell.
Twelve months earlier, in October 2025: 30 analysts, 3 Strong Buy, 17 Buy, 9 Hold, 0 Sell and 1 Strong Sell.
Price Targets
- Average Target
- $1345.80
- Median Target
- $1376.00
- High
- $1500.00
- Low
- $940.00
- Targets Published, Last 12 Months
- 54
Recent Price Targets
The 5 most recent of 54 price targets published in the last 12 months.
| Date | Firm | Analyst | Target | Price When Posted |
|---|---|---|---|---|
| Oct 8, 2026 | Cantor Fitzgerald | Carter Gould | $1,440.00 | $1,188.72 |
| Oct 7, 2026 | Morgan Stanley | Not named | $1,430.00 | $1,184.48 |
| Sep 18, 2026 | Guggenheim | Seamus Fernandez | $1,284.00 | $1,152.13 |
| Sep 15, 2026 | Berenberg Bank | Kerry Holford | $1,400.00 | $1,137.75 |
| Sep 10, 2026 | HSBC | Not named | $940.00 | $1,124.16 |
Recent Upgrades & Downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 8, 2026 | Cantor Fitzgerald | maintain | Overweight | Overweight |
| Oct 7, 2026 | Morgan Stanley | maintain | Overweight | Overweight |
| Sep 28, 2026 | JP Morgan | maintain | Overweight | Overweight |
| Sep 22, 2026 | TD Cowen | maintain | Buy | Buy |
| Sep 18, 2026 | Guggenheim | maintain | Buy | Buy |
Quantitative Rating
LLY carries a model grade of B (overall score 3 of 5), computed from six valuation and financial measures (discounted cash flow, return on equity, return on assets, debt to equity, price to earnings and price to book), each scored 1 to 5. It is not an analyst rating.
How to Read LLY Analyst Coverage
Sell-side equity analysts publish three primary outputs: ratings (Strong Buy / Buy / Hold / Sell / Strong Sell, or firm-specific equivalents), price targets, and EPS / revenue estimate revisions. Rating consensus moves slowly relative to price; it reflects 12-month directional conviction rather than near-term momentum. Price targets are more responsive but typically drift behind realized price during sharp moves. The most actionable signal for options traders is a cluster of ratings actions across multiple firms within a short window, which compresses or expands implied volatility on a horizon of days to weeks and shifts the put-call skew toward the directional consensus. The recent-actions table above shows the five most recent firm-level changes; longer histories live behind aggregator sources.
For event-driven options sizing, pair the consensus rating and target distribution with the implied-volatility surface and dealer-positioning view. Aggressive target hikes from multiple firms tend to tighten put skew (downside protection becomes relatively cheaper); aggressive cuts widen put skew. The size of the IV response in the hours after a rating change is visible on the per-ticker volatility skew page and the gamma-exposure page, both of which show how dealer hedging propagates the analyst-driven flow into the listed options chain.
Learn how analyst ratings is reported and how to read the data →
Frequently asked LLY analyst ratings questions
- What is the LLY consensus price target?
- As of the latest aggregator update, Eli Lilly and Company (LLY) carries a consensus 12-month price target of $1345.80. Target ranges run from a low of $940.00 to a high of $1500.00. The target is the average of the price targets published by sell-side equity analysts covering the name.
- What is the analyst rating consensus on LLY?
- In the October 2026 monthly count, 30 analysts rated LLY, and the distribution tilts to the Buy side: 6 Strong Buy, 19 Buy, 3 Hold, 1 Sell and 1 Strong Sell. Rating consensus moves slowly relative to price; it reflects sell-side conviction over a 12-month horizon rather than near-term momentum.
- What recent ratings actions has LLY seen?
- The five most recent ratings actions on LLY appear on the page above. Sell-side rating changes are watched for two reasons: an upgrade or downgrade with a meaningful target revision moves the consensus and can trigger short-term positioning shifts, and the firm-level rating cluster (multiple firms moving in the same direction within a short window) is a clearer signal than any single action. Options markets often price the implied-vol response within minutes of the announcement.
- How do analyst targets affect LLY options pricing?
- Analyst target revisions tend to be priced in by the lit options market within minutes of publication, but persistent target drift over weeks does correlate with implied-volatility movement. Aggressive target hikes from multiple firms inside a single quarter tighten put skew (downside protection becomes cheaper relative to upside speculation); aggressive cuts widen put skew. The most actionable read is the implied-vol response in the hours after a target change, which is visible on the per-ticker volatility skew page.